Videos

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses a study of outcomes of autologous stem cell transplantation in very elderly patients with multiple myeloma.

Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone.

Helmut Schaider, MD, associate professor, Dermatology Research Centre, The University of Queensland, Australia, discusses drug resistance in melanoma.<br /> &nbsp;

The Therapeutic Approach for Relapsed CML

Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charit&eacute; Center Gynecology, Charit&eacute; &ndash; Universitatsmedizin Berlin, discusses a randomized controlled phase II study to evaluate secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.

Roger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses a study of celecoxib versus placebo in primary breast cancer patients.&nbsp;

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> &#8203;

Peter Martin, MD,&nbsp;assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of&nbsp;medicine and&nbsp;urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with&nbsp;metastatic castration-resistant prostate cancer.&nbsp;

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.&nbsp;

Jane N. Winter, MD,&nbsp;professor of medicine, Division of Hematology/Oncology, Feinberg School of Medicine at Northwestern University, discusses the importance of identifying and treating patients with follicular lymphoma (FL) who experience progression of their disease.&nbsp;

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br /> &nbsp;

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.

Eileen O&rsquo;Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses areas she believes will be the focus of future research in pancreatic cancer.

The Therapeutic Approach for High-Risk CLL